These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1553895)

  • 21. Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone.
    Takahara A; Nakamura Y; Sugiyama A
    Eur J Pharmacol; 2008 Oct; 596(1-3):127-31. PubMed ID: 18786527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris.
    Funck-Brentano C; Coudray P; Planellas J; Motté G; Jaillon P
    Am J Cardiol; 1990 Oct; 66(10):812-7. PubMed ID: 2220578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.
    Antzelevitch C; Belardinelli L; Wu L; Fraser H; Zygmunt AC; Burashnikov A; Di Diego JM; Fish JM; Cordeiro JM; Goodrow RJ; Scornik F; Perez G
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S65-83. PubMed ID: 15378132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
    Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Severe ventricular arrhythmia secondary to indapamide-induced hypopotassemia].
    Guzzini F; Baroffio R; Coppetti D; Gasparini P
    Clin Ter; 1990 Nov; 135(4):283-7. PubMed ID: 1705875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
    Drici MD; Clément N
    Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azithromycin-induced proarrhythmia and cardiovascular death.
    Howard PA
    Ann Pharmacother; 2013 Nov; 47(11):1547-51. PubMed ID: 24285766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of morphological changes in T-U waves during bepridil therapy as a predictor of ventricular arrhythmic event.
    Kurokawa S; Niwano S; Kiryu M; Murakami M; Ishikawa S; Yumoto Y; Moriguchi M; Niwano H; Kosukegawa T; Izumi T
    Circ J; 2010 May; 74(5):876-84. PubMed ID: 20354335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology of bepridil.
    Gill A; Flaim SF; Damiano BP; Sit SP; Brannan MD
    Am J Cardiol; 1992 Apr; 69(11):11D-16D. PubMed ID: 1372785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR; Gallacher DJ; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
    Hondeghem LM
    Drug Saf; 2018 Jan; 41(1):11-17. PubMed ID: 28853038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of efficacy of proarrhythmia biomarkers in isolated rabbit hearts with attenuated repolarization reserve.
    Orosz S; Sarusi A; Csík N; Papp JG; Varró A; Farkas S; Forster T; Farkas AS; Farkas A
    J Cardiovasc Pharmacol; 2014 Sep; 64(3):266-76. PubMed ID: 24887684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale.
    Manolis TA; Manolis AA; Manolis AS
    Angiology; 2019 Feb; 70(2):103-129. PubMed ID: 29874922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciprofloxacin-induced acquired long QT syndrome.
    Prabhakar M; Krahn AD
    Heart Rhythm; 2004 Nov; 1(5):624-6. PubMed ID: 15851230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.